{"id":"mono-therapy-with-sildenafil","safety":{"commonSideEffects":[{"rate":"28","effect":"Headache"},{"rate":"10","effect":"Flushing"},{"rate":"7","effect":"Dyspepsia"},{"rate":"9","effect":"Nasal congestion"},{"rate":null,"effect":"Hypotension"},{"rate":"3","effect":"Visual disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sildenafil blocks the enzyme phosphodiesterase-5, which normally breaks down cyclic guanosine monophosphate (cGMP). By preventing cGMP degradation, sildenafil allows sustained vasodilation in vascular smooth muscle. This mechanism improves blood flow and reduces vascular resistance, with applications across multiple therapeutic areas including pulmonary hypertension and erectile dysfunction.","oneSentence":"Sildenafil inhibits phosphodiesterase-5 (PD-5) to increase cyclic GMP levels, promoting vasodilation and improving blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:10.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT04039464","phase":"PHASE3","title":"Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-08-01","conditions":"Pediatric Pulmonary Hypertension","enrollment":28},{"nctId":"NCT05556083","phase":"PHASE2","title":"Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2022-10-01","conditions":"Premature Ejaculation","enrollment":200},{"nctId":"NCT02946944","phase":"PHASE1","title":"Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism","status":"UNKNOWN","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2016-10","conditions":"Pulmonary Embolism, Intermediate-high Risk, Combination of Oral Anticoagulation Therapy and Sildenafil","enrollment":100},{"nctId":"NCT00730067","phase":"PHASE4","title":"Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension","status":"WITHDRAWN","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"COPD, Pulmonary Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revatio monotherapy"],"phase":"phase_3","status":"active","brandName":"Mono-Therapy with Sildenafil","genericName":"Mono-Therapy with Sildenafil","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sildenafil inhibits phosphodiesterase-5 (PD-5) to increase cyclic GMP levels, promoting vasodilation and improving blood flow. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}